Clinical Trial Update: A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) [Phase 2]

View source ↗

Summary

A Phase II trial tests rituximab with CC-99282 as front-line therapy for older frail patients with diffuse large B-cell lymphoma. The study, conducted by Fondaz…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CC-99282
• Rituximab (rituximab)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Diffuse Large B Cell Non-Hodgkin Lymphoma | Phase 2 | Status: RECRUITING